Hear the speakers delve into how early attention to market access can significantly influence value creation for biotech and pharmaceutical companies, as well as investors, with this panel sharing their own experiences.

A clear ‘Payer’ or Market Access strategy is key for the successful launch of healthcare products, especially with the increasingly tight scrutiny on pricing and reimbursement in all major healthcare systems.

While large cap pharmaceutical companies often incorporate Payer requirements early in the clinical development process, smaller firms and investors tend to consider these aspects later on, which can be a disadvantage. However, building a commercial strategy that does not adequately consider payer requirements puts firms at a distinct disadvantage, reducing the pool of interested partners as well as deal scope and exit value.

To help bring awareness to this topic, Scientist.com and FingerPost Consulting hosted a panel discussion on the crucial role of market access in the biotech industry. The event is a must for startup biotechs, industry investors, and personnel from large pharmaceutical companies, as it promises to broaden participants' understanding of market access and its potential to shape drug development's future. Attendees will learn the importance and timing of integrating market access considerations into their commercial planning.

Key learning objectives will include:

• Discover what market access means and why it's crucial for informed commercial decisions


• Learn from three distinct viewpoints:
  - How investors use market access to underpin robust biotech investments
  - How biotechs can harness market access to create and demonstrate value
  - How big pharma utilize market access to screen for commercial viability